Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
- DOI
- 10.1038/s41391-026-01131-6
- Published
- 2026 Sep
- Container
- Prostate cancer and prostatic diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41391-026-01131-6,
title = {Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.},
author = {Trinh QD and George DJ and Shore N and Vjaters E and Olmos D and de Santana Gomes AJP and de Andrade Mota AC and Littleton N and Srinivasan S and Verholen F and Haresh KP and Saad F},
year = {2026},
journal = {Prostate cancer and prostatic diseases},
doi = {10.1038/s41391-026-01131-6},
url = {https://doi.org/10.1038/s41391-026-01131-6}
}RIS
TY - JOUR TI - Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. AU - Trinh QD AU - George DJ AU - Shore N AU - Vjaters E AU - Olmos D AU - de Santana Gomes AJP AU - de Andrade Mota AC AU - Littleton N AU - Srinivasan S AU - Verholen F AU - Haresh KP AU - Saad F PY - 2026 JO - Prostate cancer and prostatic diseases DO - 10.1038/s41391-026-01131-6 UR - https://doi.org/10.1038/s41391-026-01131-6 ER -
APA
QD, T., DJ, G., N, S., E, V., D, O., AJP, D. S. G., AC, D. A. M., N, L., S, S., F, V., KP, H., & F, S. (2026). Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.. Prostate cancer and prostatic diseases. https://doi.org/10.1038/s41391-026-01131-6
Source records
- pubmed · retrieved 2026-09-26T02:42:47.142Z